Bone mass at final height in precocious puberty after gonadotropin-releasing hormone agonist with and without calcium supplementation.

Antoniazzi F, Zamboni G, Bertoldo F, Lauriola S, Mengarda F, Pietrobelli A, Tatò L

The Journal of clinical endocrinology and metabolism1 Mar 2003Cited by 39 (Europe PMC)

PMID12629090DOI10.1210/jc.2002-021154PepBankPUB-12629090

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone11

In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Triptorelin (Trelstar, Decapeptyl).

01HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialEfficacy outcome
In girls with central precocious puberty, pooled triptorelin regimens with or without calcium yielded final heights above initial predictions.
In plain wordsIn girls with early puberty, pooled triptorelin regimens with or without calcium yielded final heights above initial predictions.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseFinal height versus predicted height
Study
n = 48
Comparator
Predicted height at diagnosis
Outcome group
Bone and joint · Musculoskeletal
Measurements
Final height
159.9 cm
final evaluation
Predicted height at diagnosis
152.9 cm
at diagnosis
Source sentences
Summary
Final height was significantly higher than predicted height at diagnosis (159.9 +/- 6.3 cm vs. 152.9 +/- 9.6 cm; P < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
The aim of our longitudinal study was to evaluate bone mass in girls affected by central precocious puberty (CPP) that have reached final height, treated with GnRH agonist triptorelin (GnRHa), with or without calcium supplementation.
Summary · context
We studied 48 Caucasian females affected by CPP (age at diagnosis, 7.19 +/- 0.96 yr), randomly assigned to two groups: group A (n = 21) treated with GnRHa and group B (n = 27) treated with GnRHa plus calcium gluconolactate and carbonate (1 g calcium/day in two doses) for at least 2 yr.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1262909001
02HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialEfficacy outcome
In girls with central precocious puberty, triptorelin plus calcium produced higher volumetric BMD than triptorelin alone at treatment end.
In plain wordsIn girls with early puberty, triptorelin plus calcium produced higher volumetric bone density than triptorelin alone at treatment end.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseVolumetric BMD at treatment end
Study
n = 48
Comparator
Triptorelin alone
Outcome group
Bone and joint · Musculoskeletal
Measurements
Volumetric BMD
0.213 g/cm(3)
group B, triptorelin plus calcium, end of treatment
Volumetric BMD
0.192 g/cm(3)
group A, triptorelin alone, end of treatment
Source sentences
Summary
The vBMD was significantly higher in group B than in group A at the end of treatment period (0.213 +/- 0.022 g/cm(3) vs. 0.192 +/- 0.021 g/cm(3); P < 0.01) and at final evaluation (0.246 +/- 0.023 g/cm(3) vs. 0.227 +/- 0.024 g/cm(3); P < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
The aim of our longitudinal study was to evaluate bone mass in girls affected by central precocious puberty (CPP) that have reached final height, treated with GnRH agonist triptorelin (GnRHa), with or without calcium supplementation.
Summary · context
We studied 48 Caucasian females affected by CPP (age at diagnosis, 7.19 +/- 0.96 yr), randomly assigned to two groups: group A (n = 21) treated with GnRHa and group B (n = 27) treated with GnRHa plus calcium gluconolactate and carbonate (1 g calcium/day in two doses) for at least 2 yr.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1262909005
03HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialEfficacy outcome
In girls with central precocious puberty, triptorelin plus calcium produced higher volumetric BMD than triptorelin alone at final evaluation.
In plain wordsIn girls with early puberty, triptorelin plus calcium produced higher volumetric bone density than triptorelin alone at final evaluation.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseVolumetric BMD at final evaluation
Study
n = 48
Comparator
Triptorelin alone
Outcome group
Bone and joint · Musculoskeletal
Measurements
Volumetric BMD
0.246 g/cm(3)
group B, triptorelin plus calcium, final evaluation
Volumetric BMD
0.227 g/cm(3)
group A, triptorelin alone, final evaluation
Source sentences
Summary
The vBMD was significantly higher in group B than in group A at the end of treatment period (0.213 +/- 0.022 g/cm(3) vs. 0.192 +/- 0.021 g/cm(3); P < 0.01) and at final evaluation (0.246 +/- 0.023 g/cm(3) vs. 0.227 +/- 0.024 g/cm(3); P < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
The aim of our longitudinal study was to evaluate bone mass in girls affected by central precocious puberty (CPP) that have reached final height, treated with GnRH agonist triptorelin (GnRHa), with or without calcium supplementation.
Summary · context
We studied 48 Caucasian females affected by CPP (age at diagnosis, 7.19 +/- 0.96 yr), randomly assigned to two groups: group A (n = 21) treated with GnRHa and group B (n = 27) treated with GnRHa plus calcium gluconolactate and carbonate (1 g calcium/day in two doses) for at least 2 yr.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1262909006
04HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialEfficacy outcome
In girls with central precocious puberty, AP-BMD percentage gains to treatment end were greater with triptorelin plus calcium than triptorelin alone.
In plain wordsIn girls with early puberty, AP-BMD percentage gains to treatment end were greater with triptorelin plus calcium than triptorelin alone.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseAP-BMD percentage change to treatment end
Study
n = 48
Comparator
Triptorelin alone
Outcome group
Bone and joint · Musculoskeletal
Measurements
AP-BMD percentage change, start to end of treatment
20.36%
group B, triptorelin plus calcium
AP-BMD percentage change, start to end of treatment
16.16%
group A, triptorelin alone
Source sentences
Summary
The percentage change (Delta%) between the start and end of treatment period in AP-BMD and vBMD was significantly higher in group B than in group A (Delta% AP-BMD: 20.36% +/- 1.10% vs. 16.16% +/- 1.90%, P < 0.01; Delta% vBMD: 19.08% +/- 3.52% vs. 9.26% +/- 5.15%; P < 0.01)
2 context sentences(design, population, supporting numbers)
Summary · context
The aim of our longitudinal study was to evaluate bone mass in girls affected by central precocious puberty (CPP) that have reached final height, treated with GnRH agonist triptorelin (GnRHa), with or without calcium supplementation.
Summary · context
We studied 48 Caucasian females affected by CPP (age at diagnosis, 7.19 +/- 0.96 yr), randomly assigned to two groups: group A (n = 21) treated with GnRHa and group B (n = 27) treated with GnRHa plus calcium gluconolactate and carbonate (1 g calcium/day in two doses) for at least 2 yr.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1262909007
05HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialEfficacy outcome
In girls with central precocious puberty, volumetric BMD percentage gains to treatment end were greater with triptorelin plus calcium than triptorelin alone.
In plain wordsIn girls with early puberty, volumetric BMD gains to treatment end were greater with triptorelin plus calcium than triptorelin alone.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseVolumetric BMD percentage change to treatment end
Study
n = 48
Comparator
Triptorelin alone
Outcome group
Bone and joint · Musculoskeletal
Measurements
vBMD percentage change, start to end of treatment
19.08%
group B, triptorelin plus calcium
vBMD percentage change, start to end of treatment
9.26%
group A, triptorelin alone
Source sentences
Summary
The percentage change (Delta%) between the start and end of treatment period in AP-BMD and vBMD was significantly higher in group B than in group A (Delta% AP-BMD: 20.36% +/- 1.10% vs. 16.16% +/- 1.90%, P < 0.01; Delta% vBMD: 19.08% +/- 3.52% vs. 9.26% +/- 5.15%; P < 0.01)
2 context sentences(design, population, supporting numbers)
Summary · context
The aim of our longitudinal study was to evaluate bone mass in girls affected by central precocious puberty (CPP) that have reached final height, treated with GnRH agonist triptorelin (GnRHa), with or without calcium supplementation.
Summary · context
We studied 48 Caucasian females affected by CPP (age at diagnosis, 7.19 +/- 0.96 yr), randomly assigned to two groups: group A (n = 21) treated with GnRHa and group B (n = 27) treated with GnRHa plus calcium gluconolactate and carbonate (1 g calcium/day in two doses) for at least 2 yr.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1262909008
06HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialEfficacy outcome
In girls with central precocious puberty, AP-BMD gains to final evaluation were greater with triptorelin plus calcium than triptorelin alone.
In plain wordsIn girls with early puberty, AP-BMD gains to final evaluation were greater with triptorelin plus calcium than triptorelin alone.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseAP-BMD percentage change to final evaluation
Study
n = 48
Comparator
Triptorelin alone
Outcome group
Bone and joint · Musculoskeletal
Measurements
AP-BMD percentage change, start to final evaluation
61.23%
group B, triptorelin plus calcium
AP-BMD percentage change, start to final evaluation
56.97%
group A, triptorelin alone
Source sentences
Summary
and also between the start of treatment and final evaluation (Delta% AP-BMD: 61.23% +/- 1.61% vs. 56.97% +/- 1.45%, P < 0.01; Delta% vBMD: 36.69% +/- 5.01% vs. 28.01% +/- 5.76%, P < 0.01).
2 context sentences(design, population, supporting numbers)
Summary · context
The aim of our longitudinal study was to evaluate bone mass in girls affected by central precocious puberty (CPP) that have reached final height, treated with GnRH agonist triptorelin (GnRHa), with or without calcium supplementation.
Summary · context
We studied 48 Caucasian females affected by CPP (age at diagnosis, 7.19 +/- 0.96 yr), randomly assigned to two groups: group A (n = 21) treated with GnRHa and group B (n = 27) treated with GnRHa plus calcium gluconolactate and carbonate (1 g calcium/day in two doses) for at least 2 yr.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1262909009
07HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialEfficacy outcome
In girls with central precocious puberty, volumetric BMD gains to final evaluation were greater with triptorelin plus calcium than triptorelin alone.
In plain wordsIn girls with early puberty, volumetric BMD gains to final evaluation were greater with triptorelin plus calcium than triptorelin alone.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseVolumetric BMD percentage change to final evaluation
Study
n = 48
Comparator
Triptorelin alone
Outcome group
Bone and joint · Musculoskeletal
Measurements
vBMD percentage change, start to final evaluation
36.69%
group B, triptorelin plus calcium
vBMD percentage change, start to final evaluation
28.01%
group A, triptorelin alone
Source sentences
Summary
and also between the start of treatment and final evaluation (Delta% AP-BMD: 61.23% +/- 1.61% vs. 56.97% +/- 1.45%, P < 0.01; Delta% vBMD: 36.69% +/- 5.01% vs. 28.01% +/- 5.76%, P < 0.01).
2 context sentences(design, population, supporting numbers)
Summary · context
The aim of our longitudinal study was to evaluate bone mass in girls affected by central precocious puberty (CPP) that have reached final height, treated with GnRH agonist triptorelin (GnRHa), with or without calcium supplementation.
Summary · context
We studied 48 Caucasian females affected by CPP (age at diagnosis, 7.19 +/- 0.96 yr), randomly assigned to two groups: group A (n = 21) treated with GnRHa and group B (n = 27) treated with GnRHa plus calcium gluconolactate and carbonate (1 g calcium/day in two doses) for at least 2 yr.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1262909010
08HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialEfficacy outcome
In girls with central precocious puberty, bone densitometric parameters after pooled triptorelin regimens were within normal ranges for age and sex.
In plain wordsIn girls with early puberty, bone density measurements after pooled triptorelin regimens were within normal ranges for age and sex.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableBone densitometric parameters within normal range
Study
n = 48
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
In all our females with CPP treated with GnRHa, bone densitometric parameters were in the normal range for age and sex.
2 context sentences(design, population, supporting numbers)
Summary · context
The aim of our longitudinal study was to evaluate bone mass in girls affected by central precocious puberty (CPP) that have reached final height, treated with GnRH agonist triptorelin (GnRHa), with or without calcium supplementation.
Summary · context
We studied 48 Caucasian females affected by CPP (age at diagnosis, 7.19 +/- 0.96 yr), randomly assigned to two groups: group A (n = 21) treated with GnRHa and group B (n = 27) treated with GnRHa plus calcium gluconolactate and carbonate (1 g calcium/day in two doses) for at least 2 yr.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1262909011
09HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneObservational studyEfficacy outcome
In girls with central precocious puberty treated with triptorelin with or without calcium, body mass index did not differ significantly from control values.
In plain wordsIn girls with central precocious puberty treated with triptorelin with or without calcium, body mass index was not statistically different from control values.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeBody mass index
Study
n: not reported in source
Comparator
Control values
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
Body mass index and fat percentage were not statistically different from control values.
2 context sentences(design, population, supporting numbers)
Summary · context
The aim of our longitudinal study was to evaluate bone mass in girls affected by central precocious puberty (CPP) that have reached final height, treated with GnRH agonist triptorelin (GnRHa), with or without calcium supplementation.
Summary · context
We studied 48 Caucasian females affected by CPP (age at diagnosis, 7.19 +/- 0.96 yr), randomly assigned to two groups: group A (n = 21) treated with GnRHa and group B (n = 27) treated with GnRHa plus calcium gluconolactate and carbonate (1 g calcium/day in two doses) for at least 2 yr.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1262909002
10HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneObservational studyEfficacy outcome
In girls with central precocious puberty treated with triptorelin with or without calcium, fat percentage did not differ significantly from control values.
In plain wordsIn girls with central precocious puberty treated with triptorelin with or without calcium, fat percentage was not statistically different from control values.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeFat percentage
Study
n: not reported in source
Comparator
Control values
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
Body mass index and fat percentage were not statistically different from control values.
2 context sentences(design, population, supporting numbers)
Summary · context
The aim of our longitudinal study was to evaluate bone mass in girls affected by central precocious puberty (CPP) that have reached final height, treated with GnRH agonist triptorelin (GnRHa), with or without calcium supplementation.
Summary · context
We studied 48 Caucasian females affected by CPP (age at diagnosis, 7.19 +/- 0.96 yr), randomly assigned to two groups: group A (n = 21) treated with GnRHa and group B (n = 27) treated with GnRHa plus calcium gluconolactate and carbonate (1 g calcium/day in two doses) for at least 2 yr.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1262909003
11HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneObservational studyEfficacy outcome
In girls with central precocious puberty, pooled triptorelin regimens yielded nonsignificantly lower final densitometric values than controls.
In plain wordsIn girls with early puberty, pooled triptorelin regimens yielded nonsignificantly lower final bone density measurements than controls.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeFinal densitometric values
Study
n: not reported in source
Comparator
Controls
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Densitometric values at final evaluation in groups A and B together were lower than in controls, but the differences were not statistically significant.
2 context sentences(design, population, supporting numbers)
Summary · context
The aim of our longitudinal study was to evaluate bone mass in girls affected by central precocious puberty (CPP) that have reached final height, treated with GnRH agonist triptorelin (GnRHa), with or without calcium supplementation.
Summary · context
We studied 48 Caucasian females affected by CPP (age at diagnosis, 7.19 +/- 0.96 yr), randomly assigned to two groups: group A (n = 21) treated with GnRHa and group B (n = 27) treated with GnRHa plus calcium gluconolactate and carbonate (1 g calcium/day in two doses) for at least 2 yr.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-1262909004

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.